Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial
Australian biotech Mesoblast has had a rollercoaster ride working toward FDA approval of its mesenchymal cell therapy product remestemcel-L. They are seeking approval for use in patients with graft-versus-host disease (GvHD). More specifically, it is intended for pediatric patients with steroid-refractory acute graft versus host disease, or SR-aGVHD. This is a serious condition and new treatment […]
Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial Read More »
